The development of oligonucleotides, antisense oligonucleotides (ASOs), peptide drugs, and peptide therapeutics for disease treatment holds tremendous potential, yet it comes with unique challenges that require specialized analytical expertise. Oligonucleotides, being prone to instability and degradation, pose difficulties in developing accurate assays for quantifying their concentration. The presence of nucleases, enzymes capable of breaking down DNA and RNA, further complicates the accurate measurement of oligonucleotide levels in biological samples. Moreover, the production of oligonucleotides at large scales and maintaining consistent quality can be demanding.

Similarly, peptide drugs present challenges in their analysis due to their small size and inherent instability. Accurately measuring peptide concentration requires the development of precise assays, which can be hindered by their susceptibility to proteases, enzymes that degrade proteins. These characteristics of peptide drugs add complexity to the assay development process and necessitate specialized techniques to ensure accurate and reliable measurements. Overcoming these analytical hurdles is crucial for advancing the development and utilization of these valuable therapeutic molecules in scientific research and clinical practice.